All patients
Age < 65y (younger) Age > 65y ECOG 0 HER2 negative Postmenopausal status Pre- or perimenopausal status
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer - HR positive, cyclin inhibitor vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MONALEESA-2, 2016 0.76 [0.63; 0.92]
MONALEESA-3, 2018 0.72 [0.57; 0.91]
MONARCH 2, 2020 0.76 [0.61; 0.95]
PALOMA-3, 2016 0.81 [0.64; 1.03]
PENELOPE-B, 2021 0.87 [0.61; 1.24]
0.77 [0.69 ; 0.86 ] MONALEESA-2, 2016, MONALEESA-3, 2018, MONARCH 2, 2020, PALOMA-3, 2016, PENELOPE-B, 2021 5 0% 3,834 low not evaluable deaths (OS) (extension)detailed results MONALEESA-3, 2018 0.73 [0.59; 0.90]
0.73 [0.59 ; 0.90 ] MONALEESA-3, 2018 1 0% 726 NA not evaluable iDFSdetailed results PENELOPE-B, 2021 0.93 [0.74; 1.17]
0.93 [0.74 ; 1.17 ] PENELOPE-B, 2021 1 0% 1,250 NA not evaluable progression or deaths (PFS)detailed results DAWNA-1, 2021 0.42 [0.31; 0.57]
FLIPPER, 2021 0.55 [0.36; 0.84]
MONALEESA-2, 2016 0.56 [0.43; 0.72]
MONALEESA-3, 2018 0.59 [0.48; 0.73]
MONALEESA-7, 2018 0.55 [0.44; 0.69]
MONARCH 2, 2020 0.55 [0.45; 0.68]
MONARCH 3, 2017 0.54 [0.41; 0.72]
PALOMA-3, 2016 0.42 [0.32; 0.56]
0.53 [0.48 ; 0.58 ] DAWNA-1, 2021, FLIPPER, 2021, MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018, MONARCH 2, 2020, MONARCH 3, 2017, PALOMA-3, 2016 8 0% 4,299 low not evaluable CBRdetailed results MONALEESA-2, 2016 1.46 [1.02; 2.10]
MONALEESA-3, 2018 1.40 [1.01; 1.94]
MONALEESA-7, 2018 1.64 [1.16; 2.33]
MONARCH 2, 2020 2.04 [1.45; 2.85]
MONARCH 3, 2017 1.42 [0.92; 2.17]
1.59 [1.36 ; 1.86 ] MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018, MONARCH 2, 2020, MONARCH 3, 2017 5 0% 3,228 low not evaluable objective responses (ORR)detailed results DAWNA-1, 2021 1.48 [0.87; 2.51]
FLIPPER, 2021 2.90 [1.81; 4.64]
MONALEESA-2, 2016 1.81 [1.31; 2.50]
MONALEESA-3, 2018 1.75 [1.22; 2.52]
MONALEESA-7, 2018 1.64 [1.19; 2.26]
MONARCH 2, 2020 2.82 [1.88; 4.24]
MONARCH 3, 2017 1.76 [1.20; 2.59]
1.93 [1.62 ; 2.31 ] DAWNA-1, 2021, FLIPPER, 2021, MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018, MONARCH 2, 2020, MONARCH 3, 2017 7 32% 3,778 low not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-13 21:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 4,319,144,356,351,357,352,354,353,358,359
- treatments: 800,716,1404,967,1443,1406,1338,1337,1369,1375,1249,1407,1376,1411,1379,1403,1381,1380
